Transforming Outcomes: Optimizing Survival, Quality of Life & Treatment Strategies in Advanced RCC

Rana R. McKay, MD, reflects on the landscape of advanced RCC, discusses histology, subsets of kidney cancer, and IMDC criteria for prognostic stratification.

Dr Rana McKay provides insight on preferred therapeutic options for first-line treatment of RCC and how patient risk stratification influences decision making.

Reflection on biomarkers, treatment resistance, and other unmet needs in 1L treatment of advanced RCC by Rana R. McKay, MD.

Centering discussion on the CheckMate 9ER trial, Dr. McKay shares perspective of recent follow-up data of nivolumab + cabozantinib in frontline advanced RCC.

Expert perspective on CheckMate 9ER quality of life data and treatment implications for patients with advanced RCC.

Discussion on triplet therapy regimens in advanced RCC and how progressing therapeutic studies can impact its future use.

Rana McKay, MD, provides insights into decision-making strategies and consideration for treatment sequencing in advanced RCC.

Concluding the discussion, Dr Rana McKay discusses the current state of advanced RCC, potential breakthroughs, and best practices for optimal patient outcomes.